



PATENT
Attorney Docket No. I-007

RECEIVED
SEP 29 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gillies *et al.* CONFIRMATION NO.: 3473
SERIAL NO.: 09/621,268 GROUP NO.: 1642
FILING DATE: July 21, 2000 EXAMINER: K. Canella, Ph.D.
TITLE: Fc Fusion Proteins for Enhancing the Immunogenicity of Protein and Peptide Antigens

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

(2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and

the requisite Statement is below, **OR**

the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

Supplemental Information Disclosure Statement

Atty Docket No. LEX-007

Serial No. 09/621,268

Page 2 of 2

(3) after the mailing date of a **final action or notice of allowance but before the payment of the issue fee, AND**

the requisite Statement is below, **AND**

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Brian A. Fairchild, Ph.D.
Agent for Applicant
Testa, Hurwitz & Thibeault, LLP
125 High Street
Boston, Massachusetts 02110

Date: September 19, 2003

Reg. No. 48,645


Tel. No.: (617) 248-7697

Fax No.: (617) 248-7100

2682107

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT <small>OPTIONAL</small> <small>SEP 25 2003</small>				ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAMINER INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
A8	07/348,237	5/5/89	Rosenblum et al.				
A9	4,196,265	4/1/80	Koprowski et al.				
A10	4,469,797	9/4/84	Albarella				
A11	4,676,980	6/30/87	Segal et al.				
A12	4,816,567	3/28/89	Cabilly et al.				
A13	4,946,778	8/7/90	Ladner et al.				
A14	5,019,368	5/28/91	Epstein et al.				
A15	5,073,627	12/17/91	Curtis et al.				
A16	5,114,711	5/19/92	Bell et al.				
A17	5,116,964	5/26/92	Capon et al.				
A18	5,199,942	4/6/93	Gillis				
A19	5,225,538	7/6/93	Capon et al.				
A20	5,225,539	7/6/93	Winter				
A21	5,258,498	11/2/93	Huston et al..				
A22	5,314,995	5/24/94	Fell, Jr. et al.				
A23	5,359,035	10/25/94	Habermann				
A24	5,514,582	5/7/96	Capon et al.				
A25	5,541,087	7/30/96	Lo et al.				
A26	5,543,297	8/6/96	Cromlish, et al.				
A27	5,552,524	09/03/96	Basinski et al.				
A28	5,585,089	12/17/96	Queen et al.				
A29	5,609,846	3/11/97	Goldenberg				
A30	5,624,821	4/29/97	Winter et al.				
A31	5,639,725	6/17/97	O'Reilly et al.				
A32	5,645,835	7/8/97	Fell, Jr. et al.				
A33	5,650,150	7/22/97	Gillies				
EXAMINER				DATE CONSIDERED			

RECEIVED
SEP 21 2003
USPTO CENTER FOR TRADEMARKS



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.


SERIAL NO.: 09/621,268 CONF. NO.: 1642

FILING DATE: July 21, 2000 GROUP: 1642

RECEIVED
SEP 25 2003
USPTO
SEARCH CENTER 1600
900

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A34	5,650,492	7/22/97	Gately et al.			
	A35	5,667,776	9/16/97	Zimmerman et al.			
	A36	5,679,543	10/21/97	Lawlis			
	A37	5,691,309	11/25/97	Basinski et al.			
	A38	5,719,266	02/17/98	DiMarchi et al.			
	A39	5,723,125	3/3/98	Chang et al.			
	A40	5,726,044	3/10/98	Lo et al.			
	A41	5,733,876	3/31/98	O'Reilly et al.			
	A42	5,756,461	05/26/98	Stephens			
	A43	5,770,195	6/23/98	Hudziak et al.			
	A44	5,807,715	9/15/98	Morrison et al.			
	A45	5,837,682	11/17/98	Folkman et al.			
	A46	5,843,423	12/1/98	Lyman et al.			
	A47	5,854,205	12/29/98	O'Reilly et al.			
	A48	5,858,347	1/12/99	Bauer et al.			
	A49	5,885,795	3/23/99	O'Reilly et al.			
	A50	5,886,178	3/23/99	Allen et al.			
	A51	5,888,772	3/30/99	Okasinski et al.			
	A52	5,908,626	6/1/99	Chang et al.			
	A53	5,922,685	7/13/99	Rakhmilevich et al.			
	A54	6,100,387	8/8/00	Herrmann et al.			
	A55	6,169,070 B1	1/2/01	Chen et al.			
	A56	6,171,588 B1	1/9/01	Carron et al.			
	A57	6,348,192 B1	2/19/02	Chan et al.			
	A58	6,444,792 B1	9/3/02	Gray et al.			
EXAMINER				DATE CONSIDERED			



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO.: 3479

FILING DATE: July 21, 2000 GROUP: 1642

RECEIVED
SEP 29 2000
TECH CENTER 1600-2900

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTR Y CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B4	0 158 198 A1	10/16/85	EP					Y
	B5	0 211 769 A2	2/25/87	EP					Y
	B6	0 256 714 A2	2/24/88	EP					Y
	B7	0 294 703 A2	12/14/88	EP					Y
	B8	0 308 936 B1	3/29/89	EP					Y
	B9	0 314 317 B1	5/3/89	EP					Y
	B10	0 318 554 B1	6/7/89	EP					Y
	B11	0 319 012 A2	6/7/89	EP					Y
	B12	0 326 120 B1	8/2/89	EP					Y
	B13	0 350 230 A2	1/10/90	EP					Y
	B14	0 375 562 B1	6/27/90	EP					Y
	B15	0 396 387 A2	11/7/90	EP					Y
	B16	0 439 095 A2	7/31/91	EP					Y
	B17	0 511 747 A1	11/4/92	EP					Y
	B18	0 601 043 B1	6/15/94	EP					Y
	B19	0 640 619 A1	3/1/95	EP					Y
	B20	0 668 353 A1	8/23/95	EP					Y
	B21	0 706 799 A2	4/17/96	EP					Y
	B22	0 790 309 A1	8/20/97	EP					Y
	B23	21725/88	3/23/89	AU					Y
	B24	93100115.3	7/14/93	CN					N
	B25	93100115.3	7/14/93	CN				Y	Y
	B26	37 12985 A1	11/3/88	DE					N
	B27	37 12985	11/2/88	DE				Y	Y
	B28	2 292 382 A	2/21/96	GB					Y
	B29	63-267278	11/4/88	JP					N
	B30	63-267278	11/4/88	JP				Y	Y

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268

CONF. NO.: 303

FILING DATE: July 21, 2000

GROUP: 1642


RECEIVED
SEP 29 2000
USPTO CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B31	63-267296	11/4/88	JP					N
	B32	63-267296	11/4/88	JP				Y	Y
	B33	0 237 019 A2	9/16/87	EP				English counterpart of JP 63-267296	Y
	B34	WO 86/01533	3/13/86	PCT					Y
	B35	WO 88/00052	1/14/88	PCT					Y
	B36	WO 88/09344	12/1/88	PCT					Y
	B37	WO 89/02922	4/6/89	PCT					Y
	B38	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B39	WO 90/03801	4/19/90	PCT					Y
	B40	WO 91/00360	1/10/91	PCT					Y
	B41	WO 91/04329	04/04/91	PCT					Y
	B42	WO 91/08298	6/13/91	PCT					Y
	B43	WO 91/13166	9/5/91	PCT					Y
	B44	WO 91/14438	10/3/91	PCT					Y
	B45	WO 92/02240	2/20/92	PCT					Y
	B46	WO 92/08495	5/29/92	PCT					Y
	B47	WO 92/08801	5/29/92	PCT					Y
	B48	WO 92/16562	10/1/92	PCT					Y
	B49	WO 93/03157	2/18/93	PCT					Y
	B50	WO 93/10229	5/27/93	PCT					Y
	B51	WO 94/24160	10/27/94	PCT					Y
	B52	WO 94/25055	11/10/94	PCT					Y
	B53	WO 95/05468	2/23/95	PCT					Y
	B54	WO 95/21258	8/10/95	PCT					Y
	B55	WO 95/28427	10/26/95	PCT					Y
	B56	WO 96/04388	02/15/96	PCT					Y
	B57	WO 96/05309	2/22/96	PCT					Y

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO.: 13473

FILING DATE: July 21, 2000

GROUP: 1642

RECEIVED
SEP 29 2003
TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B58	WO 96/18412	6/20/96	PCT					Y
	B59	WO 96/31526	10/10/96	PCT					Y
	B60	WO 97/00317	1/3/97	PCT					Y
	B61	WO 97/00319	1/3/97	PCT					Y
	B62	WO 97/15666	5/1/97	PCT					Y
	B63	WO 97/20062	6/5/97	PCT					Y
	B64	WO 97/24440	7/10/97	PCT					Y
	B65	WO 97/26335	7/24/97	PCT					Y
	B66	WO 97/30089	8/21/97	PCT					Y
	B67	WO 97/33617	9/18/97	PCT					Y
	B68	WO 97/33619	9/18/97	PCT					Y
	B69	WO 97/34631	9/25/97	PCT					Y
	B70	WO 97/43316	11/20/97	PCT					Y
	B71	WO 98/00127	1/8/98	PCT					Y
	B72	WO 98/06752	2/19/98	PCT					Y
	B73	WO 98/28427	7/2/98	PCT					Y
	B74	WO 98/46257	10/22/98	PCT					Y
	B75	WO 98/59244	12/30/98	PCT					Y
	B76	WO 99/02709	01/21/99	PCT					Y
	B77	WO 99/03887	01/28/99	PCT					Y
	B78	WO 99/29732	6/17/99	PCT					Y
	B79	WO 99/43713	9/2/99	PCT					Y
	B80	WO 99/52562	10/21/99	PCT					Y
	B81	WO 99/53958	10/28/99	PCT					Y
	B82	WO 99/60128	11/25/99	PCT					Y
	B83	WO 99/62944	12/09/99	PCT					Y

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO.: 34

FILING DATE: July 21, 2000 GROUP: 1642

RECEIVED
SEP 23 2003
TECH CENTER 1600
USPTO

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B84	WO 99/66054	12/23/99	PCT					Y
	B85	WO 00/11033	3/2/00	PCT					Y
	B86	WO 00/34317	06/15/00	PCT					Y
	B87	WO 00/40615	7/13/00	PCT					Y
	B88	WO 00/68376	11/16/00	PCT					Y
	B89	WO 00/69913	11/23/00	PCT					Y
	B90	WO 00/78334 A1	12/28/00	PCT					Y
	B91	WO 01/07081 A1	2/1/01	PCT					Y
	B92	WO 01/10912 A1	2/15/01	PCT					Y
	B93	WO 03/015697 A2	2/27/03	PCT					Y

EXAM.
INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

C3	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," <u>Journal of Protein Chemistry</u> , 11:5:433-444.
C4	Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54:2:83-94.
C5	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.
C6	Arenberg et al. (1996), "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.
C7	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Experimental Medicine</u> , 167:612-622
C8	Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856.
C9	Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.
C10	Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.

EXAMINER

DATE CONSIDERED

SEP 25 2003
JG17
PARENT & TRADE
MARKS
SEARCHED
INDEXED
SERIALIZED
FILED

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO.: 347

FILING DATE: July 21, 2000 GROUP: 1642

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
C11	Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263.
C12	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Mol. Immunol.</u> , 30:379-386.
C13	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.
C14	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.
C15	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.
C16	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193.
C17	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.
C18	Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Nature</u> , 390:404-407.
C19	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.
C20	Brooks et al., (1994), "Integrin $\alpha_5\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.
C21	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.
C22	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138.
C23	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , 173:6:1483-1491.
C24	Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , 271:46:29461-29467.
C25	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272:36:22924-22928.
EXAMINER	DATE CONSIDERED

RECEIVED
SEP 2
USPTO
PATENT & TRADE
MARKS
SEARCHED
INDEXED
SERIALIZED
FILED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP: 1642 RECEIVED SEP 27 2003 USPTO CENTER 100-290r
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C26	Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , 337:525-531.
	C27	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.
	C28	Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.
	C29	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.
	C30	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.
	C31	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , 335:370-372.
	C32	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <u>Nature</u> , 339:394-397.
	C33	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159:1:351-358.
	C34	Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.
	C35	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.
	C36	Cohen, S. L. et al., (1996), "Human leptin characterization," <u>Nature</u> , 382:589.
	C37	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.
	C38	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.
	C39	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.
	C40	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.
	C41	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.
	C42	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , 95:10443-10448.
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP: 1642 RECEIVED SEP 25 2003 USPTO 02/29/00
EXAM. INITIATED	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C43	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166.	
C44	Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> 31:342-348.	
C45	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:7:2446-2452.	
C46	Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:15552-15558.	
C47	Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," <u>Nature</u> , 395:763-770.	
C48	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.	
C49	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.	
C50	Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.	
C51	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.	
C52	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.	
C53	Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> , 1:1:47-54.	
C54	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , 89:1428-1432.	
C55	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235.	
C56	Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>J. Immunology</u> , 160:2:6195-6203.	
C57	Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.	
C58	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , 120:6:2027-2032.	
C59	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.	
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003 SC 175		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP: 1642
EXAM. INIT. [initials]	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C60	Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , 269:91-95.	
C61	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.	
C62	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:8:2081-2805.	
C63	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Tibtech</u> , 11:42-44.	
C64	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotech</u> , 1:95-105.	
C65	Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," <u>Journal of Immunology</u> , 157:7:3165-3170.	
C66	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11:6:629-636.	
C67	He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> , 160:1029-1035.	
C68	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunol.</u> , 158:4381-4388.	
C69	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:18: 7059-7063.	
C70	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.	
C71	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7:2:159-167.	
C72	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17:6:1656-1664.	
C73	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675.	
C74	Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.	
C75	Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , 28:9:1027-1037.	
C76	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096:4:345-354 (Abstract).	
EXAMINER		DATE CONSIDERED

RECEIVED
SEP 20 2000
TECH CENTER
MAIL ROOM 2900

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

SEP 25 2003

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO. 3473

FILING DATE: July 21, 2000 GROUP: 1642 1600/290,

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C77	Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.
	C78	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake ¹ ," <u>Cancer Research</u> , 56:4998-5004.
	C79	Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C _y genes," <u>Nucleic Acids Research</u> , Vol. 14:4:1779-1789.
	C80	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.
	C81	Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , 348:555-557.
	C82	Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:6069:522-525.
	C83	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.
	C84	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci.</u> , 83:4479-4483.
	C85	Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-micorglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci.</u> , 93:11:5512-5516.
	C86	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci.</u> , 88:11120-11123.
	C87	Kappel et al., (1992), "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553
	C88	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc λ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160:6:1686-1701.
	C89	Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunotherapy</u> , 48:219-229.
	C90	Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <u>Journal Immunology</u> , 158:9:4137-4144.
	C91	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.
	C92	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 81:7922-7926.
EXAMINER		DATE CONSIDERED

RECEIVED
SEP 29 2003
SEARCH CENTER
1600/290

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

SEP 25 2003

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268 CONF. NO.: 3473

FILING DATE: July 21, 2000 GROUP: 1642

RECEIVED
SEP 29 2003
TECH CENTER 100-2900

EXAM.
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

	C93	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152:6:1233-1246.
	C94	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268:31:23311-23317.
	C95	Lazar et al., (1988), "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8:3:1247-1252.
	C96	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.
	C97	Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nature Biotechnology</u> , 15:1:35-40.
	C98	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , 174:3:561-569.
	C99	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 82:8648-8652.
	C100	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.
	C101	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Therap.</u> , 80:3:277-292.
	C102	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91:5:1706-1715.
	C103	Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci.</u> , 96:1591-1596.
	C104	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci.</u> , 96:8591-8596.
	C105	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29:2:117-120.
	C106	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84:8:2457-2466.
	C107	Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , 267:36:26166-26171.
	C108	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> , 25:137-146.
	C109	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158:5:2211-2217.

EXAMINER

DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP: 1640 RECEIVED SEP 29 2003 U.S. PATENT AND TRADEMARK OFFICE
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C110	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.
	C111	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173.
	C112	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.
	C113	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:4:473-492.
	C114	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci.</u> , 83:8258-8262.
	C115	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , 123-140.
	C116	Nedwin et al., (1985), "Human Lymphotxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13:17:6361-6373.
	C117	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.
	C118	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142.
	C119	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.
	C120	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.
	C121	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , 2:6:689-692.
	C122	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.
	C123	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264:26:15157-15160.
	C124	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.
	C125	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , 163:166-178.
	C126	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal of Immunology</u> , 142:10:3662-3667.
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 3473 FILING DATE: July 21, 2000 GROUP: 10429 SEP 29 2003
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C127	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Research</u> , 59:1036-1040.
	C128	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , 94:20:10889-10894.
	C129	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 27-53.
	C130	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , 7:2:S99-S106.
	C131	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , 343:1177-1183.
	C132	Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347.
	C133	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , 9:2:58-62.
	C134	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> , 2:3:159-173.
	C135	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.
	C136	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , 17:15:4249-4256.
	C137	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.
	C138	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci.</u> , 84:6904-6908.
	C139	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , 148:11:3433-3340.
	C140	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:13:4842-4846.
	C141	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutoin exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.
	C142	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>Journal of Immunology</u> , 163:5020-5028.
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT SEP 25 2003 PATENT		ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies et al. SERIAL NO.: 09/621,268 CONF. NO.: 34829700 FILING DATE: July 21, 2000 GROUP: 1642 RECEIVED SEARCHED INDEXED FILED JULY 2000
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C143	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon- λ and is not blocked by human IgG," <u>Journal of Immunology</u> , 137:11:3378-3382.
	C144	Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.
	C145	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci.</u> , 87:5322-5326.
	C146	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.
	C147	Stevenson et al., (1997), "Conjugation of Human Fc γ in Closed-Hinge or Open-Hinge Configuration to Fab' γ and Analogous Ligands," <u>Journal of Immunology</u> , 158:2242-2250.
	C148	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Research</u> , 60:247-267.
	C149	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , 302:305-309.
	C150	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , 143:8:2595-2601.
	C151	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , 178:2:661-667.
	C152	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.
	C153	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 th ed. 1999).
	C154	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48:5:1119-1123
	C155	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168
	C156	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.
	C157	Vagiani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.
	C158	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , 44:681-687.
	C159	Verhoeven et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.
EXAMINER		DATE CONSIDERED

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-007
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
SEP 25 2003		SERIAL NO.: 09/621,268 CONF. NO.: 3473
		FILING DATE: July 21, 2000 GROUP: 1642
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C160	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:112-20.
	C161	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:9:3662-3672.
	C162	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , 43:319-324.
	C163	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <u>Protein Engineering</u> , 1:6:493-498.
	C164	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>Journal Immunology</u> , 151: 6602-6607.
	C165	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.
	C166	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.
	C167	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269:3469-3474.
	C168	Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogenic islet transplantation," <u>Journal of Immunology</u> , 154:5590-5600.
EXAMINER		DATE CONSIDERED

2685054